Golden Grove (AU)
{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~6 mi. (Elizabeth Vale, Australia, +144 more cities)
facility
Lyell McEwin Hospital ( Site 4004)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~6 mi. (Elizabeth Vale, Australia, +247 more cities)
facility
Calvary Central Districts Hospital
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~6 mi. (Elizabeth Vale, Australia, +93 more cities)
facility
Lyell McEwin Hospital ( Site 1252)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
city
~6 mi. (Elizabeth Vale, Australia, +145 more cities)
facility
Calvary Central Districts Hospital
biomarker
Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers
condition
Colorectal Carcinoma
drug
ipilimumab, +1 more drug
drug type
immunotherapy
Tislelizumab Plus BGB-A1217 Versus Tislelizumab Versus Durvalumab When Co-administered With Concurrent Chemoradiotherapy (cCRT) in Lung Cancer
city
~6 mi. (Elizabeth Vale, Australia, +7 more cities)
facility
Lyell McEwin Hospital
condition
Non-Small Cell Lung Carcinoma
drug
chemotherapy, +3 more drugs
drug type
chemotherapy, +1 more type
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
city
~6 mi. (Elizabeth Vale, Australia, +78 more cities)
facility
Local Institution
condition
Colorectal Adenocarcinoma
drug
ipilimumab, +3 more drugs
drug type
immunotherapy, +1 more type
Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment
city
~6 mi. (Elizabeth Vale, Australia, +36 more cities)
facility
Cavalry Central Districts Hospital
condition
Melanoma
drug
pembrolizumab, +1 more drug
drug type
immunotherapy
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
city
~15 mi. (Fitzroy, Australia, +50 more cities)
facility
St. Vincent's Hospital Melbourne
condition
B-Cell Non-Hodgkin Lymphoma, +1 more condition
drug
atezolizumab, +1 more drug
drug type
immunotherapy